Effect of Oral Iron Chelator L1 on Iron Absorption in Man-Reference-Cited by-同舟云学术

Effect of Oral Iron Chelator L1 on Iron Absorption in Man

Published:1998-06 Issue:1 COOLEY'S ANEM Volume:850 Page:466-468
ISSN:0077-8923
Container-title:Annals of the New York Academy of Sciences
language:en
Short-container-title:Annals NY Acad Sci

Author:

DRESOW B.,FISCHER R.,NIELSEN P.,GABBE E. E.,PIGA A.

Publisher

Wiley

Subject

History and Philosophy of Science,General Biochemistry, Genetics and Molecular Biology,General Neuroscience

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1749-6632.1998.tb10523.x/fullpdf

Reference3 articles.

1. 1Fischer, R., R. Engelhardt, P. Nielsen, E. E. Gabbe, H. C. Heinrich, W. H. Schmiegel & D. Wurbs. 1992. Liver iron quantification in the diagnosis and therapy control of iron overload patients.InAdvances in Biomagnetism '91. M. Hoke, S. N. Erne, Y. C. Okada & G. L. Romani, Eds.: 585-588. Elsevier, Amsterdam.

2. HPLC-based measurement of the chelator 1,2-dimethyl-3-hydroxy-pyrid-4-one (L1) and its iron complex for pharmacokinetic studies in humans

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Guidelines for the monitoring and management of iron overload in patients with haemoglobinopathies and rare anaemias;British Journal of Haematology;2021-10-06

2. New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications;International Journal of Molecular Sciences;2021-05-24

3. Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases;Cells;2020-06-12

4. Dietary and pharmacological factors affecting iron absorption in mice and man (Comment for a Letter to the editor);Haematologica;2016-02-29

5. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes;Drug Design, Development and Therapy;2016-01